185
`Vol. to - 1988 Pharmaceutical: Weekblari Scientific Edition
`
`review articles
`
`Plasma or serum in therapeutic drug monitoring and clinical toxicology
`
`DONALD RlA. USES
`
`Introduction
`
`in therapeutic drug monitoring and clinical toxi-
`cology most determinations of the concentration of a
`substance are carried out in blood or blood com-
`
`ponents. Whole blood can only be analysed if the
`blood has been sampled in collecting tubes con-
`taining an anticoagulant When such samples are
`centrifuged, plasma is obtained. Therefore, plasma
`always contains one or more anticoagulants. Hep~
`aria sodium (3-100 U/ml) is most widely used for this
`purpose, but citrate, edetare, oxalate and fluoride
`are also suitable additives. Scrum is the clear liquid
`that separates from blood when blood is allowed to
`clot completer and then centrifuged. Therefore
`serum contains no fibrogen and no anticoagulants.
`The choice between whole blood on the one band
`
`Is there any difference between serum and plasma
`concentration?
`
`The expression ‘plasma concentration‘ is a part of
`the title of many articles in the literature. Reading
`these articles, however,
`it appears that serum
`samples have often been taken. The authors very
`seldom present
`their arguments for
`the choice
`between plasma or serum.
`Some of the advantages of plasma over serum
`are:
`
`~ large volume;
`— no delayed clotting;
`- less risk of haemolysis;
`— the sample is often suitable for both whole blood
`and plasma monitoring.
`Some of the disadvantages of plasma over serum
`are:
`
`and either plasma or serum on the other is clear.
`Whole blood concentrations are only measured if the
`compound is concentrated in the erythrocytes (cg.
`lead, cyanide, mercury, carbon monoxide, chlor—
`ihalirfloue),"3 if there is a fluctuating erythrocyte—
`plasma ratio (ciclosporin A),“ or because of the risk
`of loss during storage or centrit‘ngation.5
`The clinical effect of several compounds correlates
`better with the concentration in a tissue compart-
`ment than with the serum or plasma concentration.
`Considering erythrocytes as a readily available tis-
`sue, whole blood should be the matrix of choice in
`therapeutic drug monitoring ’ and toxicology.‘37
`Sometimes lymphocyte concentration can predict
`the therapeutic effect better (epirubicin, mitox~
`antrone). 9 In nearly all other cases, plasma or
`Larger available volume
`serum concentrations are measured.
`If blood is allowed to clot and is then centrifuged,
`
`— the (unknown) influence of the anticoagulant on
`the assay, the protein binding and the stability of
`the sample:
`- the (unknown) influence of additives or impurities
`in the anticoagulant on the assay and the concen-
`tration;
`— the risk of the formation of small clots (incomplete
`mixing, instability);
`-« dilution of the sample;
`- sampling is more expensive;
`— choice of anticoagulant can be confusing
`
`ADVANTAGES 0F PLASMA OVER SERUM
`
`1
`
`Uges BRA. Plasma or serum in therapeutic drug monitoring and clinical
`toxicology. Pharm chkbl [Sci] 1988;10:185-8.
`
`Abstract
`The relative merits of plasma and serum in blood analysis are reviewed.
`The expression ‘plasme concentration“ is often used in the literature,
`although serum samples have been taken. In most cases serum and plasma
`concentrations of analytes are the same. The choice depends mostly on
`the policy of the hospital or the availability of the test tubes in the ward.
`Some of the advantages of plasma over serum are large volume, no
`delayed clotting, less risk of haemolysis. In addition, the sample is often
`suitable for both whole blood and plasma monitoring. Some of the
`disadvantages of plasma over serum are the (unknown) influence of the
`anticoagulant on the assay, on the protein binding and on the stability of
`the sample, the (unknown) influence of additives or impurities in the
`anticoagulants on the assay and on the concentration, the risk of the
`
`formation of small clots and dilution of the sample.
`
`b
`
`Keywords
`Anticoagulants
`Blood coagulation
`Blood preservation
`Plasma
`Protein binding
`Serum
`
`Therapeutic drug monitoring
`Toxicology
`
`*Laboratory for Clinical and
`Forensic Toxicology and Drug
`Monitoring, Department of
`Pharmacy, University Hospital
`Groningen, PO. Box 30.001,
`9700 RB Grouingen.
`
`
`InnoPharma Exhibit 1035.0001
`
`

`

`Vol. 10 - 1988 Phormaccutirch Weskblod Scientific Edition
`186
`
`about 3o to 50% of the original volume is collected as
`serum {upper layer). A slightly larger sample (in
`general 50%), known as plasma, can be obtained by
`centrifugation of a blood sample collected in a tube
`containing an anticoagulant. Serum and plasma are
`not significantly different with respect
`to drug
`analysis.
`Despite the fact that serum is devoid of the
`proteins associated with the clotting process, the
`most important proteins (quantitatively speaking),
`such as the albumins and globulins, are present in
`similar amounts (approximately 2% Wl/VOl) in both
`serum and plasma. Thus plasma is in general pre«
`ferred because of its greater yield from blood
`samples. The greater yield the greater the amount of
`drug and the fewer the problems with sensitivity, or
`1with sampling neonates.m “
`
`Delay through time needed for cloning
`Clotting can sometimes he of long duration. This is
`especially true when samples are taken in polypro-
`pylene test tubes.r in which case clotting can continue
`even after centrifugation.
`
`Decreased risk of heemolysis
`The chlorthalidone concentration in erythrocytes
`is about 40 times as high as that in planner.8L One
`percent of haemolysis (which cannot easily be seen)
`will increase the apparent plasma concentration by
`25%. This problem is even more acute when serum
`samples are produced from whole blood.
`The separation by centrifugation should be carried
`out as quickiyas possible in order to prevent any
`effects due to lysis of the blood clot. ” This phenom-
`enon is well known in the analysis of the endogenous
`compounds potassium and iron in serum.
`
`Suitability of the sample for both whole blood and
`plasma analysis
`if several analyses have to be carried out on the
`blood of a single patient, determinations can be
`carried out in whole blood as well as plasma. from one
`blood sample containing a suitable anticoagulant. In
`bedside chemistry whole blood is preferred to
`plasma or serum, because this avoids a centri—
`fugation step.12
`
`msaovaumons or PLASMA
`
`IN RELATION
`
`ro sander
`
`The influence of the anticoagulant on the essay
`Walters and Roberts showed that heparin at a
`concentration of too U per ml interfered with the
`gentamicin BMW assay, but not with the Tl“)?
`FPIA assay.13 This effect is thought to be due to the
`inhibition of enzyme activity rather than disturbance
`of the antigenuantibody reaction. Blood collected
`into heparinized tubes usually contains approxi-
`mately 30 U of heparin per ml and at this level no
`interference with the 13le assay occurs. How-
`
`ever, plasma derived from specimens collected from
`arterial and venous blood is liker to yield erroneous
`results.
`The formation of a gentamicin—heparin complex
`has been demonstrated by Myers etei. ‘ Cipolie ct oi.
`concluded that heparinized tubes should not be used
`when collecting blood samples for assays where
`inactivation of gentarniein would give false values. ‘5
`Edetate was for gentamicin a suitable alternative.
`On the other hand, the Dutch foundation ‘Qnality
`control
`clinical drug analysis
`and toxicology’
`(KKGT) found with its quality control programme
`that edetate interfered strongly with the FPIA assay
`and not with the I":le assay of carbamazepine and
`with the EMITE‘ assay and not with FPIA assay of
`valproic acid. The reason of this interference is
`unknown (Dijkhuls IC, personal communication,
`1988).
`
`The influence of the anticoagulant on protein
`binding
`A discrepancy in the measurement of lidocaine in
`heparinized blood and in serum could be expected,
`as heparin increases the free fraction of littlocaine.16
`Lidocaine is subsequently redistributed from the
`plasma into red blood cells.
`The percentage of free ibuprofen in heparinized
`plasma is significantly higher than in non—heparin-
`ized plasma. 7 Although small doses of heparin can
`affect drug binding, the extent and variability of the
`effect depends on the biological activity of the
`heparin, and varies with the manufacturer and
`batch, time of sampling, and food intake. ‘8 Although
`the intravenous administration of heparin results in a
`high lipolytic activity in vivo and consequently
`increases the concentrations of non-esterified fatty
`acids in vitro, it is unlikely that this will happen after
`adding heparin to the tube.
`Non—esterified fatty acid can displace numerous
`drugs from their binding sites in plasma. When the
`non~esterified fatty acids concentration increases in
`vino, phenytoin will be displaced from the binding
`sites. The free phenytoin then shifts from the plasma
`into the erythrocytes, resulting in a lower phenytoin
`plasmalevel (up to ao% below its original camel)”
`The same phenomenon was found with amitrip—
`tylinc, imipramine and matprotiline.‘i The recovery
`of chlorprornazine added to heparinized plasma in
`vitro was reduced compared with that obtained with
`water or oxalated plasma.”
`
`The influence of the anticoagulant on the stability
`of the sample
`When heparin deteriorates or adsorbs onto the
`wall of the collecting tube, clotting will still ocour in a
`clear plasma sample. The pH of the sample can be
`changed by using sodium citrate, or oxalate as
`anticoagulants This change of pH may influence the
`stability of the drug in the sample (cg. atracun'urn).
`Sodium fluoride can be used as anticoagulant (cal-
`
`InnoPharma Exhibit 1035.0002
`
`

`

`
`Vol. 10 - 1988 Pharmaceutical: Weekblad Scientific Edition
`
`:87
`
`slum binder), and as a preservative (antimicrobial)
`of ethanol. Blood samples that are to be tested for
`ethanol must contain to mg sodium fluoride per ml
`during strange.2122
`
`The influence of additives or impurities in the
`anticoagulant an the assay
`Benzyl alcohol, which may be added to heparin as
`a preservative, can. disturb the fluorimetric assay of
`corticosteroicls.B Serum zinc concentrations are 16%
`higher than plasma concentrations. This phenom-
`enon was explained by a release of zinc from
`platelets during coagulation of the blood samples.”
`Keyaer er al. , however, found no difference between
`the serum and plasma zinc levels of fifty volun-
`tears”;
`
`The influence of additives or impurities in the
`anticoagulant on the concentration
`Anticoagulants can contain impurities which are
`preciser the compounds to be determined, eg. lead,
`aluminium, copper, fluoride.
`
`The risk of clot formation because of poor mixing
`or poor stability
`Unfortunately, blood samples in heparinized
`tubes are sometimes not very well mixed. In such
`cases a partially clotted sample will arrive in the
`laboratory.
`
`Impmper dilution of the sample
`We have had a number of incidents in which blood
`
`samples of about 5 ml were diluted with about I ml of
`a solution of anticoagulant (20% dilutionl). Differ-
`ences in serum and plasma transcobalamin 11 levels in
`the literature have been explained by dilution by
`EDTA or sodium fluoride solutions?
`
`Cost
`
`Sample tubes with heparin are approximately 10%
`more expensive than non-heparinized tubes.
`
`The choice of anticoagulant
`There are Several anticoagulants, each of which
`must be used in a different concentration. Examples
`are sodium heparin,
`lithium heparin, potassium
`edetate, sodium edetate, sodium citrate, and sodium
`fluoride. The differences in the influence of these
`
`anticoagulants on the various assays are largerly
`unknown.
`Differences were demonstrated between serum
`
`and plasma levels of endogenous compounds, which
`may be of sufficient magnitude to alter clinical
`interpretation of some results when using different
`radioassay procedures and different anticoagu-
`lants.“ These differences are in general larger with
`immunoassays than with chromatographic methods.
`Cholinesterase activity can be determined in serum
`or heparinized plasma. Sodium fluoride and citrate
`should not be used as anticoagulants because they
`
`depress cholinesterase activity as measured by set!~
`eral tnethods.28
`Anticoagulants used in sampling plasma can con-
`found diffusion assays by causing alterations in the
`agar gel matrix. Therefore, in the microbiological
`measurement of, for example, erythromycin, cytaras
`binegr s-fluorouracil the use of serum is recommem
`decl.
`
`Conclusion
`
`In conclusion, we can say that in most cases serum
`and plasma analyte concentrations are the same. The
`choice depends mostly on the established practice in
`the hospital or the kind of available test tubes in the
`ward. In special cases such as the determination of
`free drug levels, however,
`there are important
`differences. It is advisable, therefore, that during
`kinetic studies of drugs, the similarity of serum and
`plasma levels for the compound being studied be
`proven. Furthermore, to avoid confusion, authors
`should be careful and precise in their presentations
`so that readers are aware that blood, plasma or
`serum is the sample under discussion.
`
`References
`
`‘ Casarett Ll, Doull .l. Toxicology. The basic science of
`poisons. New York: Macmillan Publishing Company,
`3975'
`3 Moffat AC. ed. Clarke’s isolation and identification of
`drugs. 2nd ed. London: The Pharmaceutical Press,
`1936.
`3‘ Beermann B, Groschlnskyfirind M. Clinical phannacm
`kinetics of diuretics. Clin Pharmacohinet 198052315.
`I Keown PA, Stiller CR, Stawecki M, Mchchael J,
`Howson W. Pharmacokinetics and interactions of ciclo~
`sporin. In: Schindler R, ed. Clclosporin in autoimmune
`diseases. Berlin: Springer‘Verlag, 198539-42.
`5 Uges BRA, Van der Paauw HIW. Alcohol, de bleed-
`proef en de contra-expertise {Alcohoh blood test and
`counterexpertise}. Ned Forens Tijdschr 1982;2:7~9.
`" Maguire KP, Burrows GD, Norman JR, Scogglngs BA.
`Blood plasma distribution ratios of psychotropic drugs.
`Clin Chem 1930362162495.
`7 Linnoila M, Dorrity F, Jobson K. Plasma and erythro-
`cyte levels of tricyclic antidepressants in depressed
`patients. Am .I Psychiatry197833535761.
`3 De Vries EOE, Greidanus l, Mulder NH, at al. A phase
`I phamtacolrinetic study with 21—day continuous infusion
`of epirubicin. J Clin Oncol 1987;5;t445~5r.
`9 De Vries EOE. Greitlanus J, Mulder NH, at al. A phase
`1 and pharmacoltinetic study with 21-day continuous
`infusion of mitoxantrona (MK). Am Soc Clin Oncol
`19883338.
`'° Smits RV, Stewart IT. Textbook of biopharmaceutic
`analysis. Philadelphia: Lea dc Febiger, 1981 :3-16.
`” Toseland PA. Samples and sampling. In: Motfat AC,
`ed. Clarke‘s isolation and identification of drugs. and
`ed. London: The Pharmaceutical Press, I986zrrr-‘y.
`‘2 Hichs IA,
`losefsohn M. Another physician's office
`analyser:
`the Abbott vision evaluated. Clin Chem
`I987;33=8x7~a
`_
`_
`’3 Walters MI, Roberts WH. Gentamicin/hepann mter~
`actions: effects on two immunoassays and on protein
`
`InnoPharma Exhibit 1035.0003
`
`

`

`188 Vol. In - 1988 Pharmaceutisch Weekblad Scientific Editien
`
`binding. The: Drug Monitnr 1984;6:I99~202.
`“ Meyers DR, DeFehr J, Bennett WM, Patter GA, Olsen
`GD. Gentamicln binding to serum and plasma proteins.
`Clin Pharmacnl The: 19783335660.
`'5 Cipolle RI, Zaake DE, Crossley K. Gentamicin/tnbra-
`myein. Therapeutic use and serum cnneentratinn moni-
`toring. In: Taylor WI, Finn LA. eds. Individuallzing
`drug therapy. I. New York: Frank Cross Townsend Inc. ,
`1981:133.
`1‘ Bebe LM. Hen-Nch A, Davies RF, Beanlends DB.
`Mnusseau N, McGllveray IJ . Influence of protamine on
`heparine induced increases nf lidncaine free fractian.
`Res Commun Chem Pathol Pharmacol [98542:401‘
`t5.
`‘7 Pearce GA, Brawn KP. Heat inhibition of in vitro
`lipnlysis and "C ibuprofen pmtein binding in plasma
`from heparinized nraemic subjects. Life Sci 1983;
`33: 1457-66-
`" Naranjo CA, Sellers EM, Khnuw V, Alexander P, Fan
`T, Shaw 3. Vanahllity in heparin effect on serum drug
`binding. Clin Phannacol Ther 1980;28:545-511.
`’9 Schulz P, Abang A, Giammini JC, Blaschke TF,
`Giammini KM. Effect nf heparin on the red blood
`cell-tn-plasma concentration ratio of diphenylhydanmin
`and praznsin. The: Drug Monitor 1933514???
`2" Whelptnn R. Tricyclic antidepressants and neurnleptics.
`In: Curry AS, ed. Antalytical methods in human
`toxicelngy. Part I. Weinheim: Verlag Chemie, 1985:
`139*53~
`3“ Flanagan R], Widdnp 13. Clinical tnxicology. In: Curry
`AS, ed. Analytical methane in human toxicology. Part I.
`Weinheim: Verleg Chemie, 1985:37‘66.
`
`22 Freentjes W, Schute JB. Strengers Th, Verwey AMA.
`Analytiseh—ehemisehe sepecten van cle wijziging van de
`Wegenverlteerswet (1;) {Analytical and clinical aspects
`0f the change in the Traffic Act (11)}. Pharm Weehhl
`1976311134962.
`23 WEIR EB jar. Interference nf heparin containing henzyl
`alcohol
`in the flnommetric determination .of plasma
`corticosteroids. J Clin Endocrinol 1937;273:350.
`3" Foley B, Johnson SA, Haekley B, Smith JCS jr, Halsth
`IA. Zinc content of human platelets. Prue Soc Exp Biol
`Med 1968;328:2659.
`*5 Keyzer JJ, Dusting E, Walthers Bi}, Muskiet FA},
`Hindri ks FR. Van der Slik W. Zinc in plasma and serum;
`influence of contamination due to the collection tubes.
`
`Pharm Weekhl {Sci} 1933;53:248-5I.
`3“ Carmel R. Vitamin Eta-binding proteins in serum and
`plasma in various disorders. Effects of anticoagulants.
`Am J Patth 1973;69:319-25.
`” Knhasik NP, Sine HE. Results for serum and plasma
`campared in I5 selected radioassays. Clin Chem
`1978;24: 137-9-
`2" Huizinga JR, Sips CH. Evaluation of the {JV—340
`spectmphntnmetric determination for pseudocholin-
`esterase activity (EC 3.1.1.8) in human serum. .1 Clin
`Chem Clin Biochem 1987;25:161-5.
`3 Smite RV, Stewart JT. Miemhlnlngic assay methods. In:
`Textbook of biopharmaceutie analysis. Philadelphia:
`Lea 8: Febiget, 1981:249-59.
`
`Received December 1987.
`Revised April 1988.
`Accepted May 1988.
`
`InnoPharma Exhibit 1035.0004
`
`